Navigation Links
Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec
Date:3/27/2008

Up to Three-Year Integrated Drug Discovery Support Program

HAMBURG, Germany and OXFORD, England, March 27 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) announced today that the Company and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a new drug discovery agreement targeting a protease chosen by Ono.

The collaboration applies Evotec's proprietary fragment-based drug discovery platform, EVOlution(TM) to identify novel, small molecular weight compounds active against a protease target. The platform integrates, among other things, protein X-ray crystallography, computational chemistry, structural biology, biochemical, and NMR based fragment screening in combination with its high-quality fragment libraries. In the collaboration it is combined with Evotec's expertise in medicinal chemistry and ADMET to further characterize active compounds identified and optimize their potency and selectivity to generate molecules for subsequent progression into clinical trials.

Under the agreement, Ono will pay to Evotec initial payments (technology access fee) for access to Evotec's fragment-based drug discovery platform, EVOlution(TM), research funding as well as success-based milestones based on the research progress.

Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, said: "We are extremely pleased that Evotec's capabilities in drug discovery and, in particular, our proprietary EVOlution(TM) platform for fragment-based drug discovery, have been so highly regarded by Ono and that they have chosen us as their partner for this collaboration. We are confident that Evotec will contribute to Ono's drug discovery program."

"We have the highest regards for the wide range of drug discovery technologies Evotec possesses and highly anticipate the collaboration will result in identifying a novel drug having high potentials," said Daikichi Fukushima, Ph.D., Managing Director, Research Headqua
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. AcroMetrix Renews Contract With Group Services for Americas Blood Centers
11. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CVS Caremark Corporation (NYSE: CVS ) announced today ... in connection with its previously announced cash tender offers (the ... and all of its 6.250% Senior Notes due 2027 (the ... amount of its 6.125% Senior Notes due 2039, 5.750% Senior ... the "Maximum Tender Offer Notes" and together with the Any ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... , Aug. 21, 2014  SI-BONE, Inc. ( ... that pioneered the use of the iFuse Implant System, ... for fusion of the sacroiliac (SI) joint, announced that ... update to its Lumbar Fusion Medical Policy No. 91590-R4 ... procedure.  The policy states that the fusion procedure, which ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... QPT: TSX Venture Exchange, EDMONTON, May 02, 2007 ... Quest is pleased to provide an,update on the ... cancer. , Prostate cancer is the second leading ... 230,000 new cases and 30,000 deaths,per year. Current ...
... 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today ... trial,of Fampridine-SR in people with multiple sclerosis ... Andrew Goodman, M.D.,Director of the Multiple Sclerosis ... results on walking ability, leg,strength, spasticity and ...
Cached Medicine Technology:Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:8/21/2014)... August 21, 2014 It's a terrible thing ... road to a serious substance abuse issue. When that happens ... of action is getting reliable help from the qualified substance ... right facility isn’t always easy for those young adults living ... a significant addiction issue. , Thankfully there is a ...
(Date:8/21/2014)... Angeles, CA (PRWEB) August 21, 2014 Sleep ... doctors across the U.S. This provides doctors with a convenient ... who find a doctor are that much closer to finding ... condition have no idea they are experiencing this sleep ... not receive treatment at all. , Thanks to Sleep Apnea ...
(Date:8/21/2014)... ERT, a leading global ... efficacy endpoint data collection, today opened registration ... Maximizing Product Value with Optimized Endpoints. ... biopharmaceutical developers to network with leading researchers ... developing, implementing, and justifying effective strategies for ...
(Date:8/21/2014)... shirt do we put on in the morning? Do we ... joint do we want to buy lunch? We make hundreds ... have a minimal impact, it is extremely important for our ... as possible. People with ADHD often find this difficult, however. ... which bring a prompt but smaller reward instead of making ...
(Date:8/21/2014)... 2014 Bedros Keuilian’s Annual Fitness Business Summit ... attended by many people already earning seven-figure incomes. But his ... usually only open to the owners of Keuilian’s own international ... year’s Fit Body Boot Camp World Conference will also be ... fitness boot camp or are struggling with their own ...
Breaking Medicine News(10 mins):Health News:Young Adults in Pompano Beach, FL Are Finding Success With Innovative New Helpline 2Health News:Sleep Apnea Doctors US is Now Offering Complimentary Listings to Sleep Apnea Doctors Across the United States 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:ADHD children make poor decisions due to less differentiated learning processes 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3
... 22 Weight Watchers,International, Inc. (NYSE: WTW ) ... a written plan for the purpose of,selling limited amounts ... adopted in accordance with Rule 10b5-1 of the Securities ... to exercise stock,options to diversify his holdings for financial ...
... in hemodialysis patients , , FRIDAY, Feb. 22 (HealthDay News) ... control in people with diabetes gives inaccurate results for ... Hemodialysis, used to treat patients with kidney failure, involves ... machine. , This Wake Forest University Baptist Medical ...
... The following statement,was issued today by William ... Kids:, The Nebraska Legislature has delivered a ... breathe clean air by passing legislation to make,all ... urge Governor Dave Heineman to sign into law ...
... ATLANTA, Feb. 22 Rarely written about, seldom spoken,of, ... the,lives of an astonishing 40% of women and 25% ... and turn what once were ordinary,tasks and activities into ... of 3, found the varicose veins significantly,affected her life ...
... Women of the United States, we,double dare you! ... your risk of cardiovascular disease., Who,s laying down ... the,American Heart Association has challenged women across the country ... to reduce their risks.,RealAge.com, the nation,s leading healthy-lifestyle Web ...
... Mo. More than $1.1 billion a year is spent ... Missouri study reports the state has a rising number of ... with hunger. The MU Interdisciplinary Center for Food Security has ... first Missouri Hunger Atlas details the distribution of hunger in ...
Cached Medicine News:Health News:Weight Watchers COO Adopts 10b5-1 Trading Plan 2Health News:Current Blood Sugar Control Test Results 'Inaccurate' 2Health News:Approval of Nebraska Smoke-Free Legislation is Historic Win for Health 2Health News:Beyond Vanity: New Treatment Brings Relief to Women After Years of Silent Suffering 2Health News:American Heart Month Double Dares Women to Beat Health Foes 2Health News:MU research team releases first Missouri Hunger Atlas 2
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
... manufactured for use as a diluent for ... is for use on the Coulter® Counter ... IV, V, VI with three-part differential and ... The shelf life is two years from ...
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
... 12 Plus Retics is a 5-part differential ... for the Abbott CELL-DYN 3200, 3500, 3700 ... also contains nucleated red blood cells that ... CELL-DYN 4000. The assay contains automated and ...
Medicine Products: